Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin.
Oda
Yayoi
Y
Digestive Disease Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Kita-ku, Osaka, Japan.
Kou
Tadayuki
T
Watanabe
Masaki
M
Sakuma
Yojiro
Y
Taguchi
Nori
N
Kato
Yoko
Y
Kudo
Yasushi
Y
Yamauchi
Atsushi
A
Sugiura
Yasushi
Y
Ohashi
Shinya
S
Asada
Masanori
M
Fukunaga
Toyokazu
T
Kawaguchi
Kiyotaka
K
Ito
Hiroaki
H
Nakamura
Takefumi
T
Yazumi
Shujiro
S
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000821:virology; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000821:virology; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin